{"id":"stsa-1002-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Dyspnea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Arthralgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, STSA-1002 injection blocks the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response. This results in the killing of cancer cells and the slowing of tumor growth.","oneSentence":"STSA-1002 injection is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:36:41.960Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT07208591","phase":"PHASE3","title":"To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-10-31","conditions":"Acute Respiratory Distress Syndrome (ARDS)","enrollment":406},{"nctId":"NCT06038916","phase":"PHASE1, PHASE2","title":"To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2023-12-09","conditions":"Acute Respiratory Distress Syndrome","enrollment":47},{"nctId":"NCT05559125","phase":"PHASE1","title":"A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects","status":"TERMINATED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2022-11-08","conditions":"Healthy Subject","enrollment":50},{"nctId":"NCT05166837","phase":"PHASE1","title":"The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2022-01-10","conditions":"Healthy","enrollment":52},{"nctId":"NCT05702983","phase":"PHASE1","title":"The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2023-01-31","conditions":"Antineutrophil Cytoplasmic Antibody Associated Vasculitis","enrollment":20},{"nctId":"NCT05497635","phase":"PHASE1","title":"A Study of STSA-1002 in Healthy Subjects","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2022-10-14","conditions":"Healthy Subject","enrollment":26},{"nctId":"NCT05032144","phase":"PHASE1","title":"The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2021-09-28","conditions":"Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"STSA-1002 injection","genericName":"STSA-1002 injection","companyName":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","companyId":"staidson-beijing-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"STSA-1002 injection is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}